These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8499646)

  • 1. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta.
    Epling-Burnette PK; Wei S; Blanchard DK; Spranzi E; Djeu JY
    Blood; 1993 Jun; 81(11):3130-7. PubMed ID: 8499646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.
    Djeu JY; Widen R; Blanchard DK
    Blood; 1989 Apr; 73(5):1264-71. PubMed ID: 2649172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
    Singh SM; Sone S; Inamura N; Ogura T
    Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
    Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
    Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
    Wei S; Blanchard DK; McMillen S; Djeu JY
    Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
    Blanchard DK; Serbousek D; Djeu JY
    Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
    Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
    Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
    Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
    Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.
    Burdach S; Zessack N; Dilloo D; Shatsky M; Thompson D; Levitt L
    J Clin Invest; 1991 Jun; 87(6):2114-21. PubMed ID: 1828253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
    Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
    Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.
    Bendall LJ; Kortlepel K; Gottlieb DJ
    Leukemia; 1995 Apr; 9(4):677-84. PubMed ID: 7723403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: effect on susceptibility to LAK lysis.
    Blanchard DK; Djeu JY
    J Leukoc Biol; 1991 Jul; 50(1):28-34. PubMed ID: 1905335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
    Swisher SG; Economou JS; Holmes EC; Golub SH
    Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.